AMED Stock Recent News
AMED LATEST HEADLINES
Amedisys' (AMED) combination with Optum brings together two organizations committed to offering patients and their families compassionate, value-based comprehensive care.
Amedisys is a leading healthcare services company dedicated to providing clinically excellent care and support at home. Currently reporting FCF generation and proposing workforce optimization, clinical optimization, and reorganization initiatives to differentiate service offerings, Amedisys appears quite an attractive stock. If the Board recommends the offer from Option Care Health, we may see an increase in the stock price.
Amedisys (AMED) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Optum's new buyout offer is competing with another buyout offer from Option Care Health. This latest offer would be a $3.26 billion all-cash deal.
Amedisys Inc told investors it received an unsolicited $100 per share bid from UnitedHealth Group's Optum unit that may be ‘superior' to a planned merger with Option Care Health, sending its shares higher in early Monday trade. The Baton Rouge, Louisiana-based healthcare company already agreed to merge with Option Care Health in an all-stock transaction in a deal announced on May 3, 2023.
Amedisys Inc. AMED, +3.64% disclosed Monday that it had received an unsolicited cash buyout bid for $100 a share from Optum, which the at-home healthcare services company believes could be considered “superior” to the buyout deal already agreed on with Option Care Health Inc. OPCH, +2.99% in early May. Amedisys shares were still inactive in premarket trading while Option Care's stock rallied 4.7%.
Amedisys Inc said on Monday it had received an unsolicited proposal from UnitedHealth Group's health services company Optum to acquire all of its outstanding shares in an all-cash transaction worth $3.26 billion.
Amedisys (AMED) sees a year-over-year decline in the Hospice segment's revenues.
While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
For Amedisys (AMED), dealing with the continuous shortage of clinical labo, in nursing in particular, has been challenging.